The Radiation Therapy Oncology Group (RTOG) 0813 protocol requires the use of dose calculation algorithms with tissue heterogeneity corrections to compute dose on stereotactic body radiation therapy (SBRT) non‐small cell lung cancer (NSCLC) plans. A new photon dose calculation algorithm called Acuros XB (AXB) has recently been implemented in the Eclipse treatment planning system (TPS). The main purpose of this study was to compare the dosimetric results of AXB with that of anisotropic analytical algorithm (AAA) for RTOG 0813 parameters. Additionally, phantom study was done to evaluate the dose prediction accuracy of AXB and AAA beyond low‐density medium of different thicknesses by comparing the calculated results with the measurements. For the RTOG dosimetric study, 14 clinically approved SBRT NSCLC cases were included. The planning target volume (PTV) ranged from 3.2‐43.0 cc. RapidArc treatment plans were generated in the Eclipse TPS following RTOG 0813 dosimetric criteria, and treatment plans were calculated using AAA with heterogeneity correction (AAA plans). All the AAA plans were then recalculated using AXB with heterogeneity correction (AXB plans) for identical beam parameters and same number of monitor units. The AAA and AXB plans were compared for following RTOG 0813 parameters: ratio of prescription isodose volume to PTV (R100%), ratio of 50% prescription isodose volume to PTV (R50%), maximal dose 2 cm from the PTV in any direction as a percentage of prescription dose false(normalD2cmfalse), and the percentage of ipsilateral lung receiving dose equal to or larger than 20 Gy false(normalV20false). The phantom study showed that the results of AXB had better agreement with the measurements, and the difference ranged from −1.7% to 2.8%. The AAA results showed larger disagreement with the measurements, with differences from 4.1% to 12.5% for field size 5×5 cm2 and from 1.4% to 6.8% for field size 10×10 cm2. The results from the RTOG SBRT lung cases showed that, on average, the AXB plans produced lower values for R100%, R50%, and normalD2cm by 4.96%, 1.15%, and 1.60%, respectively, but higher V20 of ipsilateral lung by 1.09% when compared with AAA plans. In the set of AAA plans, minor deviation was seen for R100% (six cases), R50% (nine cases), normalD2cm (four cases), and V20 (one case). Similarly, the AXB plans also showed minor deviation for R100% (one case), R50% (eight cases), normalD2cm (three cases), and V20 (one case). The dosimetric results presented in the current study show that both the AXB and AAA can meet the RTOG 0813 dosimetric criteria.PACS number: 87.55.D‐, 87.55.dk, 87.55.kd, 87.55.km
In this study, dose prediction accuracy of Acuros XB (AXB) dose calculation algorithm beyond air gap thickness (range 2, 4, and 6 cm) in simple inhomogeneous phantoms was investigated. The evaluation of AXB was performed by comparing the doses calculated by AXB with the doses calculated by Anisotropic Analytical Algorithm (AAA) and the measured data for different field sizes (3 × 3, 5 × 5, and 10 × 10 cm2) of a 6 MV photon beam. The dose computation was performed within Eclipse treatment planning system, and measurements were acquired with a cylindrical ionization chamber. Central axis depth dose comparisons were done in solid–water material region up to 5 cm distance from air/solid—water interface. The results of AXB had better agreement with measurements at all measured points than that of AAA. The discrepancies between AXB and measured data were seen from − 3.81% to + 0.9%, whereas the AAA differences with measurement from − 3.1% to − 10.9%. The combination of the smallest test field size and the largest air gap produced the highest range (1-5 cm distance from air/solid–water interface) in dose difference (AAA: −4.0% to − 10.6% and AXB: −3.8% to + 0.6%). The AAA computational time was about 8 times faster than that of AXB. In conclusion, AXB is more appropriate to use for dose predictions, especially when low-density heterogeneities are involved.
Purpose The main purpose of this study is to demonstrate the clinical implementation of a comprehensive pencil beam scanning (PBS) daily quality assurance (QA) program involving a number of novel QA devices including the Sphinx/Lynx/parallel‐plate (PPC05) ion chamber and HexaCheck/multiple imaging modality isocentricity (MIMI) imaging phantoms. Additionally, the study highlights the importance of testing the connectivity among oncology information system (OIS), beam delivery/imaging systems, and patient position system at a proton center with multi‐vendor equipment and software. Methods For dosimetry, a daily QA plan with spot map of four different energies (106, 145, 172, and 221 MeV) is delivered on the delivery system through the OIS. The delivery assesses the dose output, field homogeneity, beam coincidence, beam energy, width, distal‐fall‐off (DFO), and spot characteristics — for example, position, size, and skewness. As a part of mechanical and imaging QA, a treatment plan with the MIMI phantom serving as the patient is transferred from OIS to imaging system. The HexaCheck/MIMI phantoms are used to assess daily laser accuracy, imaging isocenter accuracy, image registration accuracy, and six‐dimensional (6D) positional correction accuracy for the kV imaging system and robotic couch. Results The daily QA results presented herein are based on 202 daily sets of measurements over a period of 10 months. Total time to perform daily QA tasks at our center is under 30 min. The relative difference (Δrel) of daily measurements with respect to baseline was within ± 1% for field homogeneity, ±0.5 mm for range, width and DFO, ±1 mm for spots positions, ±10% for in‐air spot sigma, ±0.5 spot skewness, and ±1 mm for beam coincidence (except 1 case: Δrel = 1.3 mm). The average Δrel in dose output was −0.2% (range: −1.1% to 1.5%). For 6D IGRT QA, the average absolute difference (Δabs) was ≤0.6 ± 0.4 mm for translational and ≤0.5° for rotational shifts. Conclusion The use of novel QA devices such as the Sphinx in conjunction with the Lynx, PPC05 ion chamber, HexaCheck/MIMI phantoms, and myQA software was shown to provide a comprehensive and efficient method for performing daily QA of a number of system parameters for a modern proton PBS‐dedicated treatment delivery unit.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.